Sanofi Acquires Vigil Neuroscience for $470 Million, Including $600 Million Conditional CVR

Sanofi acquired Vigil Neuroscience for $370 million, with an equity value of approximately $470 million. Vigil shareholders will receive a non-transferrable CVR per share, entitling them to a deferred cash payment of $2 conditioned upon the first commercial sale of VG-3927. The acquisition is subject to customary conditions, including approval from Vigil shareholders and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.